Globus Medical Inc
NYSE:GMED
Net Margin
Globus Medical Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Globus Medical Inc
NYSE:GMED
|
9.7B USD |
4%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
216.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
134.9B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
131.5B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.5B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.4B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.6B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
256.5B CNY |
33%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
31.3B USD |
25%
|
Globus Medical Inc
Glance View
Globus Medical Inc., founded in 2003, has crafted a distinctive narrative in the landscape of medical technology, rooted in innovation and practicality. Emerging from a profound understanding of spinal pathologies, the company has steadily risen to become a pivotal player in the musculoskeletal sector. Its journey is steered by a commitment to addressing complex spine disorders through the development of cutting-edge products that are not only innovative but also substantially user-friendly for both surgeons and patients. This fusion of technology and practicality is what sets Globus Medical apart. The company relentlessly focuses on expanding its product offerings through significant investments in research and development, continuously pushing the envelope in areas such as minimally invasive surgery, advanced surgical approaches, and imaging, which form the core of its business operations. The heart of Globus Medical's revenue model lies in its expansive product portfolio that serves surgeons and healthcare institutions globally. Their financial engine is powered by the sales of implants and related surgical instruments, meticulously designed to improve surgical outcomes. These products span a wide array of offerings including but not limited to advanced minimally invasive techniques and sophisticated trauma solutions. Beyond the traditional revenue streams, Globus Medical has ventured into promising areas like robotic surgery, thereby augmenting its revenue sources while accessing the benefits of technological advancements. This strategic direction not only strengthens its market position but also ensures it stays at the forefront of providing value-based solutions in the ever-evolving healthcare landscape. By integrating its technological prowess with a deep understanding of clinical needs, Globus Medical continues to carve a robust path for sustainable growth and leadership in the medtech sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Globus Medical Inc's most recent financial statements, the company has Net Margin of 4.1%.
You don't have any saved screeners yet